For copyright status please check original publication.
Citation
Health, C., 2023. CADTH Reimbursement Review - Olaparib (Lynparza) - Sponsor: AstraZeneca Canada Inc. Therapeutic area: gBRCAm, HER2-negative, high-risk early breast cancer, Canadian Agency for Drugs and Technologies in Health.
Canada
Retrieved from https://coilink.org/20.500.12592/b1dgw2 on 27 Nov 2024. COI: 20.500.12592/b1dgw2.
If your institution is a member, please log into
Policy Commons from a link provided by your institution. This typically
involves logging in via a menu managed by your library.
If your institution is a member, please log into Policy
Commons from a link provided by your institution. This typically involves
logging in via a menu managed by your library.
20.500.12592/h2spdv